R
Redx Pharma PLC
LSE:REDX
Redx Pharma PLC
LSE:REDX
Price:
15 GBX
31.58%
Updated:
May 7, 2024
Redx Pharma PLC
Operating Income
|
Redx Pharma PLC
Operating Income Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
R
|
Redx Pharma PLC
LSE:REDX
|
Operating Income
-£31m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£7.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$257m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$622m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is Redx Pharma PLC's Operating Income?
Operating Income
-31m
GBP
-31m
GBP
Based on the financial report for Sep 30, 2023, Redx Pharma PLC's Operating Income amounts to -31m GBP.
What is Redx Pharma PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-25%
-25%
Over the last year, the Operating Income growth was -67%. The average annual Operating Income growth rates for Redx Pharma PLC have been -55% over the past three years , -25% over the past five years .
You don't have any saved screeners yet
